News:Diabetes Care Makes an "ADVANCE" with Better Blood Pressure Control
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
September 3, 2007 By Sabina A. Murphy, M.P.H. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Vienna, Austria: Researchers announced the results of the largest trial ever conducted in diabetics, which showed a reduction in mortality with treatment with the combination of perindopril and indapamide to lower blood pressure. The ADVANCE (Action in Diabetes and Vascular Disease) trial results were revealed at the European Society of Cardiology Congress and simultaneously published in The Lancet.
The ADVANCE trial enrolled high-risk, type 2 diabetic patients with or without a history of hypertension in a randomized, double-blind fashion. Patients received either a fixed combination of perindopril and indapamide once daily (n=5569) or matching placebo (n=5571).
At the end of the 4 year follow-up, blood pressure was lowered from 145 / 81 mmHg at baseline to 134.7 / 74.8 mmHg in the perindopril/indapamide group, a mean of 5.6 / 2.2 mmHg lower than the placebo group (p < 0.001).
The perindopril/indapamide combination reduced death by 14% over placebo, with much of the decrease coming from lower cardiovascular death, which was reduced by 18%. The primary endpoint, a composite of a variety of vascular events including cardiovascular death, stroke, MI, and new or worsening nephropathy or retinopathy, also declined with the perindopril/indapamide combination therapy (15.5% vs. 16.8%, RRR 9%, p = 0.041).
The UK Prospective Diabetes Study previously showed that reducing blood pressure confers a reduction in vascular events in hypertensive diabetic patients, but in that study the mean blood pressure at the end of follow was 145 mmHg, or 10 mmHg higher than in ADVANCE. The upcoming ACCORD trial addresses the issue of whether even lower blood pressure in diabetes will result in even fewer clinical events.
Global projections of the number of diabetics worldwide approaches 250 million for the year 2007. Professor Stephen MacMahon, presenter of the ADVANCE trial data at the ESC, noted that "If the benefits observed in ADVANCE were applied to just half the world’s diabetic population, then approximately 1.5 million deaths could be avoided over a 5-year period from 2010 to 2015."
Sources
ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): Lancet 2007; DOI:10.1016/S0140-6736(07)61303-8. http://www.thelancet.com.
